Research News

Join WhatsApp Channel 

Crack GPAT — Prepare for GPAT Online 
  • Tumor Cells Suffer Copper Withdrawal Nanofibers made of copper-binding peptides disrupt copper homeostasis in cancer cells
    21 November 2024

    Tumor Cells Suffer Copper Withdrawal Nanofibers made of copper-binding peptides disrupt copper homeostasis in cancer cells

    While toxic in high concentrations, copper is essential to life as a trace element. Many tumors require significantly more copper than healthy cells for growth a possible new point of attack for cancer treatment. In the journal Angewandte Chemie, a research team from the Max Planck Institute for Polymer Research has now introduced a novel method by which copper is effectively removed from tumor cells, killing them.

  • 15 November 2024
    Optical Biosensor Rapidly Detects Monkeypox Virus
    A new variant of human mpox has claimed the lives of approximately 5% of people with reported infections in the Democratic Republic of the Congo since 2023, many of them children. Since then, it has spread to several other countries. The World Health Organization declared the outbreak a Public Health Emergency of International Concern on August 14. In addition, a different but rarely fatal mpox variant was responsible for an outbreak that has spread to more than 100 countries since 2022.
  • 15 November 2024
    New Discovery Enables Gene Therapy for Muscular Dystrophies, Other Disorders

    RNA-based technology facilitates effective use for difficult-to-treat, large-gene diseases. Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is a big problem: size. The genes that are dysfunctional in muscular dystrophies are often extremely large, and current delivery methods can’t courier such substantial genetic loads into the body.

  • 14 November 2024
    Aptar Pharma to Commercialize Quattrii Dry Powder Inhaler Platform
    Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced that it has entered into an exclusive collaboration agreement with Cambridge Healthcare Innovations to lead the commercialization and promotion of its Quattrii Dry Powder Inhaler platform.
  • 13 November 2024
    Researchers develop nanofiber patch for treatment of psoriasis
    Researchers at the University of Copenhagen have developed a patch for easier and more effective treatment of psoriasis. The method may also be used in treatment of other inflammatory skin diseases.
  • 13 November 2024
    Glioblastoma : new treatment attacks brain tumors from multiple angles

    Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this aggressive tumor permanently disappear. The tumor cells are too varied, and the microenvironment is too tumor-friendly. Researchers at the University of Basel and University Hospital Basel have now developed an immunotherapy that not only attacks the tumor—it also turns its microenvironment against it.

  • 29 October 2024
    Heart failure mortality declining in Sweden

    A new study from Karolinska Institutet shows that heart failure mortality has decreased in Sweden over the last 20 years. The study has been published in the European Journal of Heart Failure. 

    A national study has shown that heart failure mortality has decreased in Sweden over the last two decades. Despite these improvements, the prognosis for heart failure patients remains worrying – 25 percent of those diagnosed in 2022 died within a year.

  • 29 October 2024
    RSV Vaccines Effective, But More People Need to Get Them
    The evidence is clear; individuals should get vaccinated if they have conditions that place them at risk for severe disease. For older adults and those with chronic conditions, RSV should be considered as serious as the flu, and they should get vaccinated
  • 9 October 2024
    India evolving as antimicrobial stewardship

    Study finds that in contrast to developed countries that kept resistance levels under control, a considerable increase in resistance to various classes of antibiotics occurred in ESKAPE pathogens in India over the 2010-2020 decade. The study is published in the International Journal of Antimicrobial Agents.

  • 8 October 2024
    WHO adds an HPV vaccine for single-dose use
    WHO announced that a fourth WHO-prequalified human papillomavirus vaccine product, Cecolin has been confirmed for use in a single-dose schedule. The decision is made based on new data on the product that fulfilled the criteria set out in the WHO 2022 recommendations for alternative, off-label use of HPV vaccines in single-dose schedules.
Subscribe to Research News